Cargando…

Risk-adjusted chemoradiation according to human papilloma viral status for anal cancer: a pilot study

BACKGROUND AND PURPOSE: HPV-associated or positive (HPV+) anal cancer patients may have better outcome compared to those with HPV negative (HPV−) disease. We report a planned interim analysis of a prospective registry study that tailors chemoradiation (CRT) for anal cancer according to HPV status. M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chu, William, Taggar, Amandeep, Ung, Yee, Chan, Kelvin K. W., Earle, Craig C., Karotki, Aliaksandr, Pasetka, Mark, Presutti, Joe, Wong, John, Zhang, Liying, Wong, C. Shun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10346840/ https://www.ncbi.nlm.nih.gov/pubmed/37456246 http://dx.doi.org/10.3389/fonc.2023.1183854

Ejemplares similares

The effect of prone and supine treatment positions for the pre-operative treatment of rectal cancer on organ-at-risk sparing and setup reproducibility using volumetric modulated arc therapy
por: Kim, Anthony, et al.
Publicado: (2017)

Stereotactic Radiotherapy for Pancreatic Cancer: A Single-Institution Experience
por: Glicksman, Rachel M, et al.
Publicado: (2020)

Synchronous anal canal carcinoma in a heterosexual couple
por: Mendez, Lucas C., et al.
Publicado: (2018)

Long-Term Outcomes of Chemoradiation for Anal Cancer Patients
por: Kim, Hun Jin, et al.
Publicado: (2013)

Efficacy and toxicity of chemoradiation in patients with anal cancer - a retrospective analysis
por: Koerber, Stefan Alexander, et al.
Publicado: (2014)

Brachytherapy boost after chemoradiation in anal cancer: a systematic review
por: Frakulli, Rezarta, et al.
Publicado: (2018)

Patient-Reported Outcomes After Chemoradiation in Patients With Anal Cancer: A Qualitative Analysis
por: Corrigan, Kelsey L., et al.
Publicado: (2022)

Prevalence of Anal High-Risk Human Papilloma Virus Infection and Abnormal Anal Cytology among Women Living with HIV
por: Muñoz-Hernando, Leticia, et al.
Publicado: (2022)

Penile Mondor's disease in a patient treated with radical chemoradiation for anal cancer
por: Pittaka, Maria, et al.
Publicado: (2017)

Response of FDG avid pelvic bone marrow to concurrent chemoradiation for anal cancer
por: Robinson, Maxwell, et al.
Publicado: (2020)

Anal Papilloma: An Exceptional Presentation of Fibrocystic Disease in Anogenital Mammary-Like Glands
por: Subashchandrabose, Priya, et al.
Publicado: (2015)

Quality-Adjusted Life Years and Disability-Adjusted Life Years Are Better With Concurrent Chemoradiation Therapy Than Induction Chemotherapy Followed by Chemoradiation Therapy in Nasopharyngeal Carcinoma
por: Nittala, Mary R, et al.
Publicado: (2021)

Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma
por: Thind, Govin, et al.
Publicado: (2014)

A multi-disciplinary model of survivorship care following definitive chemoradiation for anal cancer
por: Savoie, Marissa B., et al.
Publicado: (2019)

Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I)
por: Northover, J, et al.
Publicado: (2010)

Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) [Corrigendum]
por: Casadei-Gardini, A, et al.
Publicado: (2019)

Quality of life and tumor control after short split-course chemoradiation for anal canal carcinoma
por: Provencher, Sawyna, et al.
Publicado: (2010)

Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer?
por: Dewas, Claire Vautravers, et al.
Publicado: (2012)

Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier)
por: Casadei-Gardini, Andrea, et al.
Publicado: (2019)

Management of Refractory Metastatic Anal Squamous Cell Carcinoma Following Disease Progression on Traditional Chemoradiation Therapy
por: Silva, Ninoska N., et al.
Publicado: (2012)

Quantification of tumour heterogeneity and glucose metabolism on pre-chemoradiation PET/CT predicts survival in anal cancer
por: Afaq, A, et al.
Publicado: (2015)

Survival prediction models for patients with anal carcinoma receiving definitive chemoradiation: A population-based study
por: Wu, Yinhang, et al.
Publicado: (2020)

Racial disparities in receipt of standard chemoradiation in anal squamous cell carcinoma, an analysis of the National Cancer Database
por: Bian, Shelly X., et al.
Publicado: (2020)

Comparison of bulk electron density and voxel‐based electron density treatment planning
por: Karotki, Aliaksandr, et al.
Publicado: (2011)

Differential Spatial Gene and Protein Expression Associated with Recurrence Following Chemoradiation for Localized Anal Squamous Cell Cancer
por: Hernandez, Sharia, et al.
Publicado: (2023)

Concurrent and Concordant Anal and Oral Human PapillomaVirus Infections Are Not Associated with Sexual Behavior in At-Risk Males
por: Rollo, Francesca, et al.
Publicado: (2021)

Practical dose delivery verification of craniospinal IMRT
por: Lee, Young K, et al.
Publicado: (2015)

18F-FDG PET Predicts Hematologic Toxicity in Patients with Locally Advanced Anal Cancer Treated With Chemoradiation
por: David, John M., et al.
Publicado: (2019)

Long-Term Disease Control After locoregional Pelvic Chemoradiation in Patients with Advanced Anal Squamous Cell Carcinoma
por: Grave, Athénaïs, et al.
Publicado: (2022)

Impact of VMAT-IMRT compared to 3D conformal radiotherapy on anal sphincter dose distribution in neoadjuvant chemoradiation of rectal cancer
por: Dapper, Hendrik, et al.
Publicado: (2018)

Polypoid lesions at the anal canal: what do they hint?
por: Wei, Shu Chen, et al.
Publicado: (2017)

Inverted Papilloma of the Maxillary Sinus: A Recurrence Analysis According to Surgical Approaches
por: Kim, Jin Youp, et al.
Publicado: (2022)

426. Prevalence of Human Papilloma Virus, Anal, and Cervical Dysplasia in Transgender Persons: A Systematic Review of the Literature
por: Van Gerwen, Olivia T, et al.
Publicado: (2019)

Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution
por: Holliday, Emma B, et al.
Publicado: (2022)

Anal human papilloma viral infection and squamous cell carcinoma: Need objective biomarkers for risk assessment and surveillance guidelines
por: Shenoy, Santosh
Publicado: (2022)

The Real-World Experience of the Biosimilar (Grastofil(®)) to the Reference Biologic (Neupogen(®)) in Breast Cancer and Lymphoma: A Canadian Single-Centre Retrospective Study
por: Wong, Gina, et al.
Publicado: (2022)

The association between protease inhibitors and anal cancer outcomes in veterans living with HIV treated with definitive chemoradiation: a retrospective study
por: Yoder, Alison K., et al.
Publicado: (2021)

A retrospective review of the real-world experience of the Pegfilgrastim biosimilar (Lapelga®) to the reference biologic (Neulasta®)
por: Wong, Gina, et al.
Publicado: (2020)

Potential role of micro ribonucleic acids in screening for anal cancer in human papilloma virus and human immunodeficiency virus related malignancies
por: Al Bitar, Samar, et al.
Publicado: (2021)

Patients with newly diagnosed cervical cancer should be screened for anal human papilloma virus and anal dysplasia: Results of a pilot study using a STELLA computer simulation and economic model()
por: Ehrenpreis, Eli D., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_01pikqs0fo2r48oplntvvaoh8u